BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomised, double-blind study of continuous REVLIMID® (lenalidomide) for the treatment of patients 65 years or older with newly diagnosed multiple myeloma show a clinically significant improvement in progression-free survival (PFS), the primary endpoint of the study. The data were presented at the annual meeting of the American Society of Hematology.
